Novo Nordisk A/S (NVO) Holdings Raised by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 36.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,237 shares of the company’s stock after acquiring an additional 25,488 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Novo Nordisk A/S were worth $4,490,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. boosted its position in shares of Novo Nordisk A/S by 41.9% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 145,455 shares of the company’s stock valued at $6,708,000 after acquiring an additional 42,938 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Novo Nordisk A/S by 14.0% during the 2nd quarter. Wells Fargo & Company MN now owns 1,301,934 shares of the company’s stock valued at $60,046,000 after acquiring an additional 159,619 shares during the last quarter. First Trust Advisors LP boosted its position in shares of Novo Nordisk A/S by 4,736.6% during the 2nd quarter. First Trust Advisors LP now owns 466,631 shares of the company’s stock valued at $21,521,000 after acquiring an additional 456,983 shares during the last quarter. GW Henssler & Associates Ltd. boosted its position in shares of Novo Nordisk A/S by 8.8% during the 2nd quarter. GW Henssler & Associates Ltd. now owns 207,481 shares of the company’s stock valued at $9,569,000 after acquiring an additional 16,848 shares during the last quarter. Finally, Sivik Global Healthcare LLC bought a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at approximately $2,306,000. Institutional investors and hedge funds own 6.84% of the company’s stock.

A number of research analysts have recently commented on NVO shares. Deutsche Bank reiterated a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, October 4th. Guggenheim started coverage on Novo Nordisk A/S in a research report on Monday, October 8th. They set a “buy” rating for the company. Bank of America downgraded Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Monday, October 8th. Pareto Securities downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Friday, October 5th. Finally, Zacks Investment Research downgraded Novo Nordisk A/S from a “buy” rating to a “sell” rating in a research report on Wednesday, October 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $64.00.

Shares of NVO opened at $45.38 on Friday. The firm has a market capitalization of $111.52 billion, a P/E ratio of 18.11, a P/E/G ratio of 2.40 and a beta of 0.75. Novo Nordisk A/S has a 52-week low of $41.23 and a 52-week high of $58.37.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Thursday, November 1st. The company reported $0.58 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.58. The company had revenue of $4.31 billion during the quarter, compared to the consensus estimate of $4.11 billion. Novo Nordisk A/S had a return on equity of 81.50% and a net margin of 34.94%. On average, analysts anticipate that Novo Nordisk A/S will post 2.45 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Novo Nordisk A/S (NVO) Holdings Raised by Mirae Asset Global Investments Co. Ltd.” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/12/08/novo-nordisk-a-s-nvo-holdings-raised-by-mirae-asset-global-investments-co-ltd.html.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Read More: How the Consumer Price Index (CPI) is calculated?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply